



## **Sphere Medical Holding PLC**

(“Sphere Medical” or “the Company”)

### **Successful completion of initial patient evaluations of lead product, Proxima**

**6 September 2010:** Sphere Medical, the UK-based medical monitoring innovator, is pleased to announce that it has successfully completed the first ‘patient attached’ clinical evaluation of its Proxima system, the revolutionary microanalyser-based blood analysis system for use in Intensive Care Units (ICU) and Operating Rooms (OR). This is a key clinical milestone for the company in the development of Proxima.

The Proxima system is being developed for critical care applications and uses Sphere Medical’s patented microanalyser technology. The microanalyser is integrated into existing patient fluid lines to allow the rapid measurement of a panel of blood parameters, including glucose blood gases and electrolytes required for the management of critically ill patients.

Rapid feedback will support more efficient and effective control of therapies such as blood sugar (glycaemic) control and weaning from ventilation, which is expected to improve patient outcome and reduce the cost of care. In addition, the system will help reduce excessive blood loss caused by frequent sampling, and decrease risk of transmission of blood borne infection.

Sphere previously announced the successful demonstration of the microanalyser performance in an *in-vitro* analyser when compared to a commercial laboratory analyser. The objectives of the current trial were to investigate the effects of directly attaching the microanalyser system into patient fluid lines and to make an initial evaluation of sensor function in blood drawn directly from the patients’ in-dwelling cannulae.

The systems performed very well throughout the study demonstrating the viability of the use model. The company plans to carry out further trials to demonstrate that the analytical performance of the microanalyser can be maintained in the ‘patient attached’ mode of operation.

The study was undertaken in healthy volunteers at the clinical trial unit of the West Suffolk Hospital, Bury St. Edmunds, UK. The Chief Investigator was Dr. John Hall, Consultant in Medical Research at West Suffolk Hospital NHS Trust, who commented:

“We are really pleased that Sphere chose West Suffolk Hospital for this trial and are delighted with the encouraging results obtained. As an anaesthetist, I am really excited about the possible benefits that this technology offers in the monitoring of patients in the operating theatre and intensive care.”

Dr. Stuart Hendry, CEO of Sphere Medical observed:

“This is a major step in the path towards regulatory approval and product launch for Proxima. We have already demonstrated that the technology used in this product is capable of analysing critical blood parameters with a performance that is equivalent to that of the current standard of care laboratory analysers. We have a series of clinical evaluations planned over the next months to demonstrate the ability to provide high quality, reliable, real-time data at the patient’s bedside.”



**About Sphere Medical**

Sphere Medical is developing highly innovative monitoring products to provide clinical and economic benefits in the critical care environment, based on the Company's proprietary microsensor technology. The products allow minimally invasive, real time measurement of clinical chemistry parameters and therapeutic drug concentrations, giving healthcare professionals the information they require to more effectively manage therapy and optimise patient outcomes. Sphere Medical was founded in 2002 and is based in Cambridge, UK.

For more information, please visit [www.spheremedical.com](http://www.spheremedical.com), or contact:

**Dr. Stuart Hendry**  
Chief Executive Officer  
Sphere Medical Holding PLC  
Tel: +44 (0)1223 875222

**Tim Anderson, Jessica Fontaine**  
Buchanan Communications  
Tel: +44 (0) 20 7466 5000